This promising antibody, XmAb 5592, presents a unique mechanism of action targeting interleukin-17A with superior potency. Differing from conventional antibodies, it functions as a bipartite modulator, associating to both the molecule and a modulating domain, leading to reduction of IL-17A secretion and biological disruption of its cascade. Initia